Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report

Thorac Cancer. 2021 Jun;12(12):1927-1930. doi: 10.1111/1759-7714.13983. Epub 2021 May 7.

Abstract

Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non-small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression-free survival of patients with ALK gene-sensitive mutations. However, the response of patients with rare ALK rearrangements to tyrosine kinase inhibitors remains unknown. Here, we report a rare case of striatin (STRN)-ALK-positive NSCLC showing primary resistance to first-line therapy alectinib and limited clinical activity of crizotinib in the alectinib-resistant setting.

Keywords: ALK rearrangement; STRN-ALK; alectinib; crizotinib; non-small cell lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anaplastic Lymphoma Kinase / therapeutic use*
  • Carbazoles / pharmacology
  • Carbazoles / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Drug Resistance, Neoplasm
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Carbazoles
  • Piperidines
  • Protein Kinase Inhibitors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • alectinib